Verified peer comparison
MCK vs LLY
McKesson Corporation compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.
MCK
McKesson Corporation
$189.43
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
LLY
Eli Lilly and Company
$782.10
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
Company-specific comparison
Business exposure
MCK: Health Care Distributors
LLY: Pharmaceuticals
Upside lens
MCK: Growth in complex medicines can increase distribution, provider-services and data demand. The US Oncology Network and related services can deepen relationships with community practices and manufacturers. Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.
LLY: obesity drug adoption and pipeline expansion
Risk lens
MCK: Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk. Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics. Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.
LLY: supply constraints and valuation expectations
Verified sources
McKesson Reports Fiscal 2026 Fourth-Quarter ResultsMcKesson Corporation · earningsVerified
McKesson Corporation Investor RelationsMcKesson Corporation · companyVerified
Fetched: 7/12/2026, 12:00:00 AM UTC
Open original sourceMcKesson SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified
Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified
Fetched: 7/11/2026, 12:00:00 AM UTC
Open original sourceForm 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified
LLY editorial research profileAlphaVue Research · editorialVerified
Fetched: 7/11/2026, 12:00:00 AM UTC